Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea, for example. These ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...